Despite clinical genomics defining MF UPN:638574 as JAK2-negative sAML, single cell analysis of purified CD34+ cells clearly showed the leukemic mutations were acquired in the founding MPN clone (Figure 1A). This evidence concerns the gene CD34 and myeloproliferative neoplasm.